Guangzhou Shenda Biological Products Technology Co., Ltd. (hereinafter referred to Shenda company) is an international joint venture established cooperatively by Guangzhou Nansha Asset Management Company and a US-owned company. It mainly develops, produces and sells Rabbit monoclonal antibody immunohistochemistry diagnostic reagents and the related products.
Being founded in 2006, Shenda company has the authorization of the patent products of the biological technology on the world's advanced rabbit monoclonal antibody, and uses the authorizing products to develop and industrialize the medical diagnostic reagents propitious to the domestic market. Shenda company is devoted to provide immunohistochemistry diagnostic reagents with a better quality and a more reasonable prize for domestic market of medical diagnostic reagents, and thus, fills the gaps in the domestic market of such products and improves the current conditions of China's medical industry which, for a long term, depends on imports of such products from abroad.
Shenda company aims to become a domestic leader in producing independent high-quality medical diagnostic reagent products, to create an excellent industrial brand, to offer a strong product support for the early diagnosis of the disease, prognosis, and clinical treatment and to enhance the international competitiveness of our country's industry of biological products.
With the authorization of the rabbit monoclonal antibody patent technology, Shenda company has developed a series of rabbit monoclonal antibody immunohistochemical reagent products. Compared with the mouse monoclonal antibody, rabbit monoclonal antibody has the following advantages:
1. It has a high affinity and can identify more epitopes;
2. It can identify many antigens that do not produce immunity in the mice;
3. It is inclined to a throughput screening of the fusion cells. Rabbit monoclonal antibody serves as the diagnostic product. For a long time, the rabbit's immune system offers good antibody reagents for the research and diagnosis. Many small molecule compounds and peptides can lead to effective immune response in the body of the rabbits. Therefore, the rabbit polyclonal antibody has always been used for drug screening and clinical diagnosis, while the rabbit monoclonal antibody technology, through making out high-quality rabbit monoclonal antibody products, provide for the research and clinical work better diagnostic reagents than rabbit monoclonal antibody with a higher specificity and a lower background¡£
